Adherence Monitor for Substance Use Disorder Treatment

项目摘要 目前SBIR计划的目标是开发一种新的非侵入性、护理点检测 为接受药物使用障碍治疗的患者提供的装置。新设备将是 能够通过以下方式监测进展并核实患者遵守处方治疗的情况 检测在尿液中释放的复合黏附标记的存在和水平， 首次提供了一种能够现场监测服药依从性的设备 临床试验和患者治疗计划中的治疗结果。我们的计划要发展 这一新的护理方法使用表面增强拉曼光谱(SERS)来 检测和量化药物依从性示踪剂，利用公司独有的 检测患者尿液中黏附生物标记物的纳米颗粒表面包衣化学 样本。我们的表面增强拉曼技术在适当的 纳米颗粒表面的制备--依赖于分子振动的唯一性 区分和鉴定尿液中黏附生物标志物的特征--IS 它不需要样品制备或化学操作就可以检测出 尿样。

Project Summary The aim of the present SBIR program is to develop a new noninvasive, point-of-care testing device for patients undergoing treatment for substance use disorder. The new device will be capable of monitoring the progress and verifying patient adherence to prescribed treatment by detecting the presence and level of a compounded adherence marker released in the urine, providing for the first time a device capable of at-site monitoring of medication adherence for treatment outcome in clinical trials and patient treatment programs. Our program to develop this new point-of-care approach uses surface-enhanced Raman spectroscopy (SERS) for detecting and quantifying the medication adherence tracer, utilizing the Company's unique nanoparticle surface-coating chemistry to detect the adherence biomarker in a patient's urine sample. A significant advantage of our surface-enhanced Raman technique on a properly prepared nanoparticle surface -- relying on the uniqueness of the molecular vibrational signature for differentiation and identification of the adherence biomarkers present in urine -- is that it requires no sample preparation or chemical manipulation to detect the biomarker in the urine sample.